Merck initiates Phase 3 study evaluating dengue vaccine candidate

Merck (MRK) announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes, regardless of prior dengue exposure. Recruitment for the trial has begun, and the first participants are now enrolling in Singapore. The primary endpoints of the study are safety and efficacy of a single dose of V181 in preventing symptomatic virologically confirmed dengue (VCD) of any severity, due to any of the four dengue serotypes, regardless of prior dengue exposure.